Paul Trippier

Affiliations: 
Pharmaceutical Sciences Texas Tech University Health Sciences Center 
Google:
"Paul Trippier"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rahman MS, Kumari S, Esfahani SH, et al. (2021) Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. Journal of Medicinal Chemistry
Jayaraman S, Kocot J, Esfahani SH, et al. (2021) . The Journal of Pharmacology and Experimental Therapeutics
Penning TM, Jonnalagadda S, Trippier PC, et al. (2021) Aldo-Keto Reductases and Cancer Drug Resistance. Pharmacological Reviews. 73: 1150-1171
Trippier PC, Huwaimel BI, Bhakta M, et al. (2020) Discovery of Halogenated Benzothiadiazine Derivatives with Anticancer Activity. Chemmedchem
Kinarivala N, Morsy A, Patel R, et al. (2020) An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening. Acs Pharmacology & Translational Science. 3: 931-947
Ashraf-Uz-Zaman M, Shahi S, Akwii R, et al. (2020) Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. European Journal of Medicinal Chemistry. 209: 112866
Maalouf K, Makoukji J, Saab S, et al. (2020) Exogenous Flupirtine as Potential Treatment for CLN3 Disease. Cells. 9
Kumari S, Carmona A, Tiwari AK, et al. (2020) Amide Bond Bioisosteres: Strategies, Synthesis and Successes. Journal of Medicinal Chemistry
Morsy A, Trippier PC. (2020) Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor. Acs Chemical Biology
Morsy A, Trippier PC. (2019) Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad
See more...